Picture of Sun Pharmaceutical Industries logo

SUNPHARMA — Sun Pharmaceutical Industries News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Brief: Sun Pharma Announces Us FDA Acceptance Of Supplemental Biologics License (Sbla) Application For Ilumya® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis

March 16 (Reuters) - Sun Pharmaceutical Industries Ltd SUN.NS:

SUN PHARMA ANNOUNCES US FDA ACCEPTANCE OF SUPPLEMENTAL BIOLOGICS LICENSE (SBLA) APPLICATION FOR ILUMYA® (TILDRAKIZUMAB-ASMN) FOR THE TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS

SUN PHARMA - FDA REGULATORY ACTION DATE FOR ILUMYA SBLA EXPECTED BY OCTOBER 29, 2026

Source text: ID:nPn7NWHdSa

Further company coverage: SUN.NS

 ((((Reuters.Briefs@thomsonreuters.com;));))

Recent news on Sun Pharmaceutical Industries

See all news